Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE

Plain-language summary

This study evaluates activation of the interferon pathway in different forms of childhood-onset systemic lupus erythematosus (SLE). Patients diagnosed with SLE before the age of 18 who have kidney involvement can take part. It is a study without an assigned phase and is still enrolling participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Meyer Children's Hospital IRCCS

Intervention

Assessment activation of interferon pathway

Start date

6/7/2023

Estimated completion

12/31/2025

Countries

Italy

Related genes

Locations

• Florence, Italy
• Genova, Italy
• Rozzano, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of SLE arising before the age of majority (until the age of 18 years) according to SLICC and/or EULAR criteria 2019;
* Clinical, laboratory and/or histologic evidence of renal involvement manifested before the age of 18 years;
* Signature of informed consent.

Exclusion Criteria:

* Onset of renal disease after the age of 18 years;
* SLE secondary to drugs or associated with other diseases such as systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, and other connectivities.